Published in N Engl J Med on January 27, 2005
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation (2010) 2.15
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging (2012) 2.03
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA (2009) 1.75
Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail (2009) 1.74
Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol (2007) 1.70
Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet (2005) 1.51
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.51
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet (2014) 1.47
Segmental duplications mediate novel, clinically relevant chromosome rearrangements. Hum Mol Genet (2009) 1.44
Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest (2007) 1.40
AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond) (2012) 1.29
Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease. Circulation (2011) 1.24
Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest (2010) 1.17
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol (2008) 1.15
GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest (2010) 1.15
UBE2A, which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-linked mental retardation syndrome. Am J Hum Genet (2006) 1.14
Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol (2010) 1.14
Autophagy in cardiovascular biology. J Clin Invest (2015) 1.14
The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart (2007) 1.12
Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J (2009) 1.12
Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol (2006) 1.07
Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med (2010) 1.07
Tuning flux: autophagy as a target of heart disease therapy. Curr Opin Cardiol (2011) 1.05
Mutation in the γ2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res (2014) 1.00
Sarcomere gene mutations in hypertrophy and heart failure. J Cardiovasc Transl Res (2010) 0.99
Hypertrophic cardiomyopathy in 2012. Circulation (2012) 0.98
Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation (2007) 0.98
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
A novel clinician interface to improve clinician access to up-to-date genetic results. J Am Med Inform Assoc (2013) 0.97
Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J (2012) 0.96
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
Cardiac Pathology in Glycogen Storage Disease Type III. JIMD Rep (2012) 0.95
Hypertrophic cardiomyopathy. Heart Fail Clin (2010) 0.95
Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound (2008) 0.93
Genetics and disease of ventricular muscle. Cold Spring Harb Perspect Med (2014) 0.92
Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet Med (2008) 0.92
Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.90
Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell Res (2014) 0.88
LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet (2010) 0.87
Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy. Circ Heart Fail (2009) 0.86
Danon disease: clinical features, evaluation, and management. Circ Heart Fail (2014) 0.86
Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation. Pediatr Cardiol (2009) 0.85
Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn (2010) 0.85
Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol (2014) 0.85
Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time. Genet Med (2010) 0.85
Hypertrophic cardiomyopathy: a review. Clin Med Insights Cardiol (2015) 0.83
Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis (2013) 0.83
Disturbance of cardiac gene expression and cardiomyocyte structure predisposes Mecp2-null mice to arrhythmias. Sci Rep (2015) 0.82
Genetic considerations in hypertrophic cardiomyopathy. Prog Cardiovasc Dis (2012) 0.81
Danon Disease Due to a Novel LAMP2 Microduplication. JIMD Rep (2013) 0.80
The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev (2014) 0.80
LAMP-2 deficiency (Danon disease). Acta Myol (2007) 0.80
iPS cell modeling of cardiometabolic diseases. J Cardiovasc Transl Res (2012) 0.80
The 3T3-L1 adipocyte glycogen proteome. Proteome Sci (2013) 0.79
Heart failure and loss of metabolic control. J Cardiovasc Pharmacol (2014) 0.79
Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders. J Am Coll Cardiol (2016) 0.79
Genes, geography and geometry: the "critical mass" in hypertrophic cardiomyopathy. J Mol Diagn (2008) 0.77
The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol (2015) 0.77
Clinical screening and genetic testing. Clin Lab Med (2010) 0.77
Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. Cell Res (2016) 0.77
Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies. Arrhythm Electrophysiol Rev (2013) 0.76
PLEKHM2 mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction. Hum Mol Genet (2015) 0.76
Prioritizing disease candidate proteins in cardiomyopathy-specific protein-protein interaction networks based on "guilt by association" analysis. PLoS One (2013) 0.76
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension (2016) 0.76
Clinical Spectrum of PRKAG2 Syndrome. Circ Arrhythm Electrophysiol (2016) 0.76
Reversible transition from a hypertrophic to a dilated cardiomyopathy. ESC Heart Fail (2015) 0.75
Serial observations and mutational analysis of an adoptee with family history of hypertrophic cardiomyopathy. Cardiol Res Pract (2010) 0.75
Asymptomatic young man with Danon disease. Tex Heart Inst J (2014) 0.75
Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev (2016) 0.75
Using genetic testing to guide therapeutic decisions in cardiomyopathy. Curr Treat Options Cardiovasc Med (2013) 0.75
A novel homozygous mutation at the GAA gene in Mexicans with early-onset Pompe disease. Acta Myol (2013) 0.75
Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. Pediatr Cardiol (2016) 0.75
Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group. BMC Neurol (2015) 0.75
An Unusual Type of Localized Hypertrophic Cardiomyopathy With Wolf Parkinson White Syndrome Presenting With Pulmonary Edema. Cardiol Res (2012) 0.75
Cardiomyopathy as presenting sign of glycogenin-1 deficiency-report of three cases and review of the literature. J Inherit Metab Dis (2016) 0.75
Hypertrophic Cardiomyopathy with Unusual Extensive Scarring Pattern: Danon Disease. Methodist Debakey Cardiovasc J (2017) 0.75
Glycogen storage diseases and cardiomyopathy. N Engl J Med (2005) 0.75
Danon disease for the cardiologist: case report and review of the literature. J Community Hosp Intern Med Perspect (2017) 0.75
Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy. Int J Med Sci (2016) 0.75
Genetics of inherited arrhythmias in children. Indian Pacing Electrophysiol J (2008) 0.75
Clinical screening and genetic testing. Heart Fail Clin (2010) 0.75
Mendelian forms of structural cardiovascular disease. Curr Cardiol Rep (2013) 0.75
Cardiomyopathy classification: ongoing debate in the genomics era. Biochem Res Int (2012) 0.75
Danon disease: intrafamilial phenotypic variability related to a novel LAMP-2 mutation. J Inherit Metab Dis (2010) 0.75
AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System. Circ Res (2017) 0.75
LAMP2 shines a light on cardiomyopathy in an athlete. HeartRhythm Case Rep (2017) 0.75
A case of familial hypertrophic cardiomyopathy emphasizes the importance of parallel screening of multiple disease genes. Clin Res Cardiol (2011) 0.75
Sequences of five potential recombination sites encoded close to an immunoglobulin kappa constant region gene. Proc Natl Acad Sci U S A (1979) 9.31
Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments. Cell (1980) 8.77
Identification of a putative second T-cell receptor. Nature (1986) 7.90
Production of homozygous mutant ES cells with a single targeting construct. Mol Cell Biol (1992) 7.23
Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation (2005) 6.85
Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A (1981) 6.67
A kappa-immunoglobulin gene is formed by site-specific recombination without further somatic mutation. Nature (1979) 6.54
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science (1998) 5.98
A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell (2001) 5.77
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med (1999) 5.61
Cloning specific segments of the mammalian genome: bacteriophage lambda containing mouse globin and surrounding gene sequences. Proc Natl Acad Sci U S A (1977) 5.28
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet (1997) 5.11
Antibody diversity. Science (1978) 5.06
The arrangement and rearrangement of antibody genes. Nature (1979) 4.88
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med (2000) 4.30
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med (1992) 4.20
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell (1993) 4.13
Intervening sequence of DNA identified in the structural portion of a mouse beta-globin gene. Proc Natl Acad Sci U S A (1978) 4.02
Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet (1997) 3.91
Multiple related immunoglobulin variable-region genes identified by cloning and sequence analysis. Proc Natl Acad Sci U S A (1978) 3.88
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature (1987) 3.81
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
Structure and expression of a mouse major histocompatibility antigen gene, H-2Ld. Proc Natl Acad Sci U S A (1982) 3.73
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A (2012) 3.72
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
A mouse model of familial hypertrophic cardiomyopathy. Science (1996) 3.69
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
High capacity gel preparative electrophoresis for purification of fragments of genomic DNA. Anal Biochem (1978) 3.42
Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol (2005) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Transcription of mouse kappa chain genes: implications for allelic exclusion. Proc Natl Acad Sci U S A (1980) 3.38
Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature (1987) 3.37
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature (1982) 3.34
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med (2008) 3.30
A human MSX1 homeodomain missense mutation causes selective tooth agenesis. Nat Genet (1996) 3.24
Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol (2010) 3.21
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet (1995) 3.18
Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation (2012) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Structure of wild-type and mutant mouse beta 2-microglobulin genes. Cell (1982) 2.97
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest (1999) 2.95
Progression to diabetes in nonobese diabetic (NOD) mice with transgenic T cell receptors. Science (1993) 2.94
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome) N Engl J Med (1994) 2.82
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2012) 2.78
Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2012) 2.76
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med (1989) 2.70
Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl Acad Sci U S A (1999) 2.70
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet (2002) 2.67
Comparison of circadian rhythm patterns in Tako-tsubo cardiomyopathy versus ST-segment elevation myocardial infarction. Am J Cardiol (2012) 2.66
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64
An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest (2000) 2.56
Hypertrophic cardiomyopathy. Anesthesiology (2006) 2.54
Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2011) 2.54
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53